{"prompt": "['MC1575', '44', 'Amendment 2', 'must also demonstrate an absolute increase of at least 0.5 cm', 'from the MSD.', 'c.', 'See Section 11.32 for details in regards to the requirements', 'for PD via FDG-PET imaging.', 'Stable Disease (SD): Neither sufficient shrinkage to qualify for PR,', 'nor sufficient increase to qualify for PD taking as reference the', 'MSD.', '11.433', 'Evaluation of Non-Target Lesions & Non-target Lymph Nodes', 'Complete Response (CR): All of the following must be true:', 'a.', 'Disappearance of all non-target', 'lesions.', 'b. Each non-target lymph node must', 'have a reduction in short axis to', '<1.0 cm.', 'c. Normalization of tumor biomarkers', 'Non-CR/Non-PD:', 'Persistence of one or more non-target', 'lesions or non-target lymph nodes and/or', 'maintenance of tumor marker level above', 'the normal limits.', 'Progression (PD):', 'At least one of the following must be', 'true:', 'a.', 'At least one new malignant lesion,', 'which also includes any lymph node', 'that was normal at baseline (<1.0 cm', 'short axis) and increased to >1.0 cm', 'short axis during follow-up.', 'b. Unequivocal progression of existing', 'non-target lesions and non-target', 'lymph nodes. (NOTE: Unequivocal', 'progression should not normally', 'trump target lesion and target lymph', 'node status. It must be representative', 'of overall disease status change.)', 'c. See Section 11.32 for details in', 'regards to the requirements for PD', 'via FDG-PET imaging.', '11.44 Overall Objective Status', 'The overall objective status for an evaluation is determined by combining the', \"patient's status on target lesions, target lymph nodes, non-target lesions, non-\", 'target lymph nodes, and new disease as defined in the following tables:', '11.441', 'For Patients with Measurable Disease', 'Non-Target Lesions &', 'Target Lesions &', 'Non-Target Lymph', 'New', 'Overall Objective', 'Target Lymph Nodes', 'Nodes', 'Sites of Disease', 'Status', 'CR', 'CR', 'No', 'CR', 'CR', 'Non-CR/Non-PD', 'No', 'PR', 'Protocol Version Date:16Aug2018']['MC1575', '45', 'Amendment 2', 'Non-Target Lesions &', 'Target Lesions &', 'Non-Target Lymph', 'New', 'Overall Objective', 'Target Lymph Nodes', 'Nodes', 'Sites of Disease', 'Status', 'CR', 'PR', 'No', 'PR', 'Non-CR/Non-PD', 'CR/PR', 'Not All Evaluated*', 'No', 'PR**', 'CR', 'SD', 'Non-CR/Non-PD', 'No', 'SD', 'Not All Evaluated*', 'CR', 'Not all Evaluated', 'Non-CR/Non-PD', 'No', 'Not Evaluated (NE)', 'Not All Evaluated*', 'Unequivocal PD', 'CR', 'PD', 'Yes or No', 'PD', 'Non-CR/Non-PD', 'Not All Evaluated*', 'CR/PR/SD/PD/Not all', 'Unequivocal PD', 'Yes or No', 'PD', 'Evaluated', 'CR', 'CR/PR/SD/PD/Not all', 'Non-CR/Non-PD', 'Yes', 'PD', 'Evaluated', 'Not All Evaluated*', '* *See Section 11.431', '* NOTE: This study uses the protocol RECIST v1.1 template dated 2/16/2011. For data collection', 'and analysis purposes the objective status changed from SD to PR in the MCCC protocol', 'RECIST v1.1 template as of 2/16/2011 and to match RECIST v1.1 requirements.', '11.45 Symptomatic Deterioration', 'Patients with global deterioration of health status requiring discontinuation of', 'treatment without objective evidence of disease progression at that time, and not', 'either related to study treatment or other medical conditions, should be reported', 'as PD due to \"symptomatic deterioration.\" Every effort should be made to', 'document the objective progression even after discontinuation of treatment due', 'to', 'symptomatic deterioration. A patient is classified as having PD due to', '\"symptomatic deterioration\" if any of the following occur that are not either', 'related to study treatment or other medical conditions:', 'Weight loss >10% of body weight.', 'Worsening of tumor-related symptoms.', 'Decline in performance status of >1 level on ECOG scale.', '12.0', 'DESCRIPTIVE FACTORS', '12.1', 'Diagnosis: Pheochromocytoma VS. Paraganglioma', '12.2', 'Baseline MIBG statuses: Positive VS. Negative VS. Unknown', '12.3', 'Prior history of TKI use: Yes for this cancer or other condition VS. no VS. unknown', '12.4', 'Prior chemotherapy therapy for this cancer: Yes VS. no.', '12.5', 'Bone disease: Yes VS. no.', '12.6', 'Secretory functional: Yes VS. no.', '12.7', 'Inherited associated genetic syndrome: Yes VS. no VS. unknown', '12.8', 'Bone modulating therapy (e.g., zoledronic acid, denosumab, etc.): Yes VS. no.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}